Targeting proteostatic mechanisms to inhibit LRRK2-mediated neurodegeneration and neuropathology

靶向蛋白抑制机制抑制 LRRK2 介导的神经变性和神经病理学

基本信息

批准号：
10807879
负责人：
Annie E Hiniker
金额：
$ 64.86万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-21 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10807879
关键词：
Alzheimer&apos s Disease Alzheimer&apos s disease pathology Automobile Driving Autopsy Biological Models Brain CRISPR interference Cell physiology Clinical Complex Data Defect Degradation Pathway Dementia Disease Electrophysiology (science)Frontotemporal Lobar Degenerations Gene Mutation Genes Goals Guanosine Triphosphate Phosphohydrolases Human Immunofluorescence Immunologic Induced pluripotent stem cell derived neurons LRRK2 gene Lead Lewy Body Dementia Measures Mediating Membrane Microtubules Molecular Mus Mutation Nerve Degeneration Neurodegenerative Disorders Neurons Organoids Pathology Pathway interactions Patients Phosphotransferases Proteins Proteomics Role STEM research Substantia nigra structure Synapses System TRIM Gene Tauopathies Testing Time Tissues Work aged brain tissue cell type cohort frontal lobe insight knock-down misfolded protein mutant neurodegenerative dementia neuropathology neurotoxicity new therapeutic target novel novel therapeutics overexpression prion-like protein TDP-43 protein aggregation protein degradation proteostasis response screening synuclein synucleinopathy tau Proteins tau aggregation therapeutic target transcriptomics ubiquitin-protein ligase

项目摘要

Neurodegenerative dementias, such as Alzheimer's disease (AD), frontotemporal lobar degeneration, and Lewy body dementia, are caused by abnormalities in proteostasis and accumulation of misfolded prion-like proteins in the brain. Mutations in the Leucine-rich repeat kinase 2 (LRRK2) gene result in diverse neuropathology, including tauopathy, synucleinopathy, TDP-43 proteinopathy, and AD pathology. Patients with LRRK2 mutations frequently develop clinical dementia, and nearly half of patients with LRRK2-driven neurodegeneration develop tau or other pathology instead of synucleinopathy. LRRK2 is therefore a key regulator controlling protein aggregation and neurodegeneration, and defining the mechanisms by which LRRK2 mutations drive such varied prion-like pathology may lead to novel targeted therapeutics. The proposed study aims to characterize the proteostatic mechanisms upstream and downstream of LRRK2 using patient-derived neurons and rare postmortem LRRK2 patient brain tissue. The study has three goals. First, to define the role of LRRK2’s subcellular localization in its cellular functions and degradation, with a particular focus on LRRK2 microtubule association and endolysosomal activation. Second, to test the extent to which newly identified LRRK2 protein degradation pathways rescue neurotoxicity in patient-derived aged neurons and other disease relevant systems. Third, to define the mechanisms by which LRRK2 mutations can drive both synucleinopathy and tauopathy using real-time quaking-induced conversion (RT-QuIC), detailed neuropathology, and cell-type specific transcriptomics on a rare cohort of LRRK2 patient brain tissues. Overall, these studies should begin to define the mechanisms by which LRRK2 drives myriad neuropathology and provide insight into the relevance of LRRK2 as a therapeutic target for tauopathies.

神经退行性痴呆，例如阿尔茨海默病 (AD)、额颞叶病变性和路易体痴呆是由蛋白质稳态异常引起的大脑中富含亮氨酸的重复序列中错误折叠的朊病毒样蛋白的积累。激酶 2 (LRRK2) 基因导致多种神经病理学，包括 tau 蛋白病、突触核蛋白病、 TDP-43 蛋白病和 AD 病理学患者经常出现 LRRK2 突变。临床痴呆，近一半 LRRK2 驱动的神经退行性疾病患者会出现 tau 蛋白因此，LRRK2 是控制突触核蛋白病或其他病理的关键调节因子。蛋白质聚集和神经变性，并定义 LRRK2 的机制突变驱动如此多样的朊病毒样病理学可能会导致新的靶向治疗。拟议的研究旨在表征上游和下游的蛋白质抑制机制 LRRK2 使用患者来源的神经元和罕见的死后 LRRK2 患者脑组织。这项研究有三个目标：首先，明确 LRRK2 的亚细胞定位在其细胞中的作用。功能和降解，特别关注 LRRK2 微管关联和其次，测试新鉴定的LRRK2蛋白的内溶酶体激活程度。降解拯救途径患者来源的老化神经元和其他疾病的神经毒性第三，明确 LRRK2 突变驱动两者的机制。使用实时震动诱导转换 (RT-QuIC) 的突触核蛋白病和 tau 蛋白病，详细对罕见的 LRRK2 患者大脑队列进行神经病理学和细胞类型特异性转录组学研究总的来说，这些研究应该开始确定 LRRK2 驱动的机制。无数的神经病理学，并深入了解 LRRK2 作为治疗靶点的相关性对于tau蛋白病。